INS and diabetes mellitus: Additionally, a sub-analysis of REDUCE-IT showed a significant risk reduction of primary endpoints across tertiles of waist circumference, and the risk reduction was independent of abdominal obesity.176 In the subgroup of patients from the JELIS trial diagnosed with diabetes, there was a 22% decrease in incidence of CV events.177 Thus, EPA may offer particular benefits for patients with diabetes as compared with EPA/DHA mixed formulations, possibly due to improved insulin sensitivity in addition to the other pleiotropic effects discussed in this review (Figure 3).